Showing 171-180 of 10218 results for "".
Considerations for Treatment Downtime After Laser Therapy in Scar Repair
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/considerations-for-treatment-downtime-after-laser-therapy-in-scar-repair-/18625/E. Victor Ross, MD discusses how treatment downtime influences his approach for treating scars. His goal, he said, is to achieve the highest degree of efficacy possible with laser used as mono- or combination therapy while being mindful of patients' comfort levels with the associated recovery periodThe State of Academic Dermatology
https://practicaldermatology.com/topics/practice-management/the-state-of-academic-dermatology/18843/In this edition of Derm Insider, host Neal Bhatia, MD sits down with Jane Grant-Kels, MD, Sheila Fallon Friedlander, MD, and Kevin Cooper, MD to discuss the challenges and rewards of academic dermatology. From meeting aggressive budgets to dealing with EMRs, academicians face many of the same demandLet's Talk about YouTube and why your Practice should have one
https://practicaldermatology.com/topics/practice-management/let-s-talk-about-youtube-and-why-your-practice-should-have-one/19116/Any form of healthcare, dental and veterinarian practice should have a YouTube account. It is known that people prefer to watch a video to learn and understand something, rather than read an article or look at a picture. YouTube gives your practice the chance to educate your patients or clients.Adjusting to a Paradigm Shift in Documentation
https://practicaldermatology.com/topics/practice-management/adjusting-to-a-paradigm-shift-in-documentation/21681/Clinicians can navigate changing rules by selecting technologies that accommodate rapid shifts in documentation.The State of AI in Dermatology
https://practicaldermatology.com/issues/january-february-2025/the-state-of-ai-in-dermatology/32927/The term “artificial intelligence” (AI) has been inescapable since OpenAI released ChatGPT to the public in November 2022.Starting a Systemic Therapy in Atopic Dermatitis or Psoriasis
https://practicaldermatology.com/series/pa-perspectives/Starting-a-Systemic-Therapy-in-Atopic-Dermatitis-or-Psoriasis/26644/In this video, Andrew Mastro, MS, PA-C, a board-certified physician assistant (PA) at the Illinois Dermatology Institute in Chicago, discusses how to talk to patients about starting a systemic therapy in atopic dermatitis or psoriasis; how to keep the conversation to 7 minutes; and the importance ofPart 1, 1726 nm lasers: Five dermatologists discuss the laser’s benefits and drawbacks for treating acne and other skin conditions
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24339/Chapter 1 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about how they have brought in the new 1726 nm wavelength lasers into their practices, what skin conditions it is most benChitotriosidase: Providing Confirmation of Sarcoidosis When ACE Fails
https://practicaldermatology.com/topics/clinical-case-reports/chitotriosidase-providing-confirmation-of-sarcoidosis-when-ace-fails/26642/Chitotriosidase: Providing Confirmation of Sarcoidosis When ACE FailsFirst Medication for Severe Frostbite; Biosimilar to Humira with Interchangeability Status Approved; Two Late-Stage AD Candidates Advance
https://practicaldermatology.com/series/dermwire-tv/first-medication-for-severe-frostbite-biosimilar-to-humira-with-interchangeability-status-approved-two-late-stage-ad-candidates-advance/20267/In this episode of DermWireTV, the first medication to treat severe frostbite is approved by the FDA; the first high-concentration biosimilar to Humira with interchangeability status will soon be available in the US; and two companies with late-stage atopic dermatitis candidates provide key updates.DermWireTV: Zoryve Approved; New SDPA President; Project Determi-Nation; Stelara for Pediatric PsA
https://practicaldermatology.com/topics/psoriasis/dermwiretv-zoryve-approved-new-sdpa-president-project-determi-nation-stelara-for-pediatric-psa/20115/FDA has approved Zoryve from Arcutis Biotherapeutics for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The novel formulation of roflumilast cream 0.3% is indicated for once-daily application. Stelara (ustekinumab) from Janssen is now approve